Kenneth Mobeck Acquires 5,000 Shares of FocalTherics (NASDAQ:FOCL) Stock

FocalTherics (NASDAQ:FOCL) CFO Kenneth Mobeck purchased 5,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was acquired at an average cost of $4.75 per share, with a total value of $23,750.00. Following the completion of the acquisition, the chief financial officer directly owned 181,610 shares of the company’s stock, valued at $862,647.50. The trade was a 2.83% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

FocalTherics Stock Down 2.3%

Shares of NASDAQ:FOCL opened at $4.26 on Wednesday. FocalTherics has a 12 month low of $1.30 and a 12 month high of $6.40. The stock’s 50-day moving average is $5.38. The company has a current ratio of 1.34, a quick ratio of 0.99 and a debt-to-equity ratio of 1.79. The company has a market cap of $159.66 million, a price-to-earnings ratio of -4.14 and a beta of -0.04.

FocalTherics (NASDAQ:FOCL) last announced its earnings results on Friday, August 14th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). FocalTherics had a negative return on equity of 175.45% and a negative net margin of 56.26%.The company had revenue of $13.20 million during the quarter. As a group, equities analysts predict that FocalTherics will post -0.78 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

FOCL has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of FocalTherics in a report on Monday. Wall Street Zen cut FocalTherics from a “hold” rating to a “sell” rating in a research note on Saturday. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of FocalTherics in a research report on Tuesday, June 2nd. Mizuho set a $15.00 price target on FocalTherics and gave the company an “outperform” rating in a report on Friday, July 17th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $4.00 price objective on shares of FocalTherics in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $7.75.

Hedge Funds Weigh In On FocalTherics

A number of hedge funds and other institutional investors have recently bought and sold shares of FOCL. Leonteq Securities AG bought a new position in FocalTherics in the fourth quarter valued at approximately $313,000. Kovack Advisors Inc. acquired a new position in shares of FocalTherics in the 4th quarter valued at $53,000. Rock Springs Capital Management LP lifted its stake in shares of FocalTherics by 1.3% in the 4th quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the company’s stock valued at $4,233,000 after purchasing an additional 16,500 shares during the period. Flax Pond Capital LLC bought a new stake in FocalTherics in the fourth quarter valued at about $2,623,000. Finally, SmartHarvest Portfolios LLC bought a new position in FocalTherics during the first quarter worth about $38,000. 62.74% of the stock is owned by institutional investors.

Key Stories Impacting FocalTherics

Here are the key news stories impacting FocalTherics this week:

• Positive Sentiment: FocalTherics insiders collectively purchased 116,000 shares for approximately $551,000 at $4.75 per share. Buyers included CEO Ryan Rhodes, CFO Kenneth Mobeck, General Counsel Sanket Shah, SVP Steven Annen, and several directors. The coordinated open-market purchases may signal that company leadership views recent weakness as an attractive entry point. FocalTherics insider buying report
• Positive Sentiment: Director Lance Willsey made the largest purchase at 50,000 shares, while CEO Ryan Rhodes bought 21,000 shares. Other executives and directors increased their holdings by roughly 2.8% to 196%, strengthening the insider-buying signal. FocalTherics director transaction filing
• Neutral Sentiment: Recent filings show several institutional investors initiated positions, and institutions collectively own 62.74% of FocalTherics. While this indicates continued professional-investor interest, the disclosed purchases vary considerably in size and do not establish a clear near-term catalyst.
• Neutral Sentiment: A recent article characterized FocalTherics as targeting market leadership following a “record-breaking quarter,” but the available report provides insufficient financial detail to independently assess the claim. FocalTherics market leadership article
• Negative Sentiment: The company’s latest quarterly loss was $0.39 per share, substantially worse than the expected $0.20 loss, on revenue of $13.20 million. FocalTherics also reported a negative net margin of 56.26% and analysts expect a full-year loss of approximately $0.78 per share, keeping profitability and financing risk in focus.
• Negative Sentiment: Analyst opinion is mixed: although some firms maintain Buy or Outperform ratings and a $7.75 consensus target, Piper Sandler rates the stock Neutral with a $4 target, while Wall Street Zen recently downgraded it to Sell. Shares also remain below their 50-day moving average of $5.38, reflecting continued technical weakness.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.